Objective(s): To investigate and compare quantitative accuracy of kidney absorbed dose measures made from both 2D and 3D imaging in patients receiving 177LuDOTATATE (Lutate) for treatment of neuroendocrine tumours (NETs). Methods: Patients receiving Lutate therapy underwent both whole body planar imaging and SPECT/CT imaging over the kidneys at time points 0.5, 4, 24, and 96-120 hours after injection. Planar data were corrected for attenuation using transmission data, and were converted to units of absolute activity via two methods, using either a calibration standard in the field of view or relative to pre-voiding image total counts. Hand drawn regions of interest were used to generate time activity curves and kidney absorbed dose estimate...
Background: Recently, 177Lu-dotatate therapy for neuroendocrine tumours has received regulatory appr...
The aim of this proof-of-concept study is to propose a simplified personalized kidney dosimetry proc...
Abstract Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelle...
Abstract Background This study aims to assess both feasibility and accuracy of renal dosimetry imagi...
BACKGROUND: Radionuclide therapy can be individualized by performing dosimetry. To determine absorbe...
BACKGROUND: Lu-177-(DOTAO,Tyr3) octreotate is a new treatment modality for disseminated neuroendocri...
International audienceWe compared the radiation-absorbed dose obtained from a two dimensional (2D) p...
Purpose Fractionated peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is increasingl...
Aim Peptide receptor radionuclide therapy (PRRT) with (177) Lu-HA-DOTATATE has evolved as a new path...
Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide su...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 pati...
The aim of this proof-of-concept study is to propose a simplified personalized kidney dosimetry proc...
Purpose: Patient-specific dosimetry is required to ensure the safety of molecular radiotherapy and t...
Background: Recently, 177Lu-dotatate therapy for neuroendocrine tumours has received regulatory appr...
The aim of this proof-of-concept study is to propose a simplified personalized kidney dosimetry proc...
Abstract Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelle...
Abstract Background This study aims to assess both feasibility and accuracy of renal dosimetry imagi...
BACKGROUND: Radionuclide therapy can be individualized by performing dosimetry. To determine absorbe...
BACKGROUND: Lu-177-(DOTAO,Tyr3) octreotate is a new treatment modality for disseminated neuroendocri...
International audienceWe compared the radiation-absorbed dose obtained from a two dimensional (2D) p...
Purpose Fractionated peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is increasingl...
Aim Peptide receptor radionuclide therapy (PRRT) with (177) Lu-HA-DOTATATE has evolved as a new path...
Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide su...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 pati...
The aim of this proof-of-concept study is to propose a simplified personalized kidney dosimetry proc...
Purpose: Patient-specific dosimetry is required to ensure the safety of molecular radiotherapy and t...
Background: Recently, 177Lu-dotatate therapy for neuroendocrine tumours has received regulatory appr...
The aim of this proof-of-concept study is to propose a simplified personalized kidney dosimetry proc...
Abstract Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelle...